15.40Open15.40Pre Close0 Volume221 Open Interest240.00Strike Price0.00Turnover39.35%IV0.92%PremiumDec 20, 2024Expiry Date13.07Intrinsic Value100Multiplier19DDays to Expiry2.33Extrinsic Value100Contract SizeAmericanOptions Type0.7434Delta0.0140Gamma14.59Leverage Ratio-0.2121Theta0.0913Rho10.84Eff Leverage0.1885Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet